DDInter998 DDInter782
Ivermectin is a semi-synthetic antiparasitic medication derived from avermectins, a class of highly-active broad-spectrum antiparasitic agents isolated from the fermentation products of _Streptomyces avermitilis_. Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1a</sub>) and 10% 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro­-25-(1-methylethyl)avermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1b</sub>). Ivermectin is mainly used in humans in the
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Ivermectin {u} (Compound) binds {v} (Gene) NR1H4
Ivermectin {u} (Compound) upregulates {v} (Gene) TRAPPC6A
Ivermectin {u} (Compound) downregulates {v} (Gene) HSPD1
Ivermectin {u} (Compound) causes {v} (Side Effect) Eosinophilia
Ivermectin (Compound) binds NR1H4 (Gene)
Ivermectin (Compound) upregulates TRAPPC6A (Gene)
Ivermectin (Compound) downregulates HSPD1 (Gene)
Ivermectin (Compound) causes Eosinophilia (Side Effect)